We investigate various approaches of gene delivery for effective gene-based therapies and create animal models that mimic the molecular mechanisms of disease
.@InstVisionParis researchers reported on systemic and local immune response to intraocular #AAV vector administration in non-human primates in @MolTherapy Methods & Clinical Development (#MTM). https://t.co/rNvFuBhqZM
Mice can see color, but only for the upper visual field (behavior by @denmanlab, @rclayreid, retinal physiology by @kfrankelab, @teulerlab, @mameister4). WHY? Our new paper @eLife may provide a possible answer. https://t.co/hfxcCYFoN1
Anyone interested in retinal regeneration who got excited by the recently published paper in @nature should read this thread. Important word of caution on the interpretation of data.
In these unusual times, make sure to avoid the panic and keep yourself informed about the facts. Check out our Faculty's top recommendations on the #coronavirus family and #COVID19 👉 https://t.co/P2REw54vDF #COVID#CoronavirusOutbreak
Coverage by @nature on gene editing CRISPR/Cas9 approach to CEP290 related blindness in a patient via #retina#surgery. Congrats Mark Pennesi @CaseyEye ! Best wishes that you patient does well. Historic! https://t.co/hwfdE0UBi4
Thrilled to share our latest publication on cortical astrocyte development 😊 Many thanks to all coauthors, with a special mention for Solène Clavreul, @LivetJean @LamiaeAdm @E_Beaurepaire and their outstanding contribution https://t.co/3kXJdLSAZw
After Valentina Emiliani yesterday, the @InstVisionParis still in the spotlight at #Sfn2019 with José Sahel discussing optogenetic strategies for vision restoration
Today we describe prime editing, a very versatile new approach to genome editing in human cells without cutting the DNA double helix. We integrated a reverse transcriptase with a disabled CRISPR enzyme to copy virtually any edit from an engineered guide RNA into a target site...